Medication Mechanisms — Differentiate major classes of psychotropic medications by mechanism of action and indications

Historical Context & Motivation

The development of psychotropic medications represents one of the most transformative chapters in the history of mental health treatment. Before the mid-twentieth century, severe psychiatric disorders were managed primarily through institutionalization, psychosurgery, and rudimentary sedation. The serendipitous discovery that certain chemical compounds could target specific neurotransmitter systems—and thereby alleviate symptoms of psychosis, depression, and anxiety—ushered in the era of biological psychiatry. Understanding this history is essential for the EPPP because it contextualizes how current pharmacological classifications emerged and why mechanism of action remains central to prescribing decisions.

These milestones reveal a recurring pattern: each breakthrough illuminated a different neurotransmitter pathway, which in turn informed new drug development. The central question for clinicians and for the EPPP is straightforward yet layered—how do the major classes of psychotropic medications differ in their mechanisms of action, and how do those mechanisms map onto clinical indications and side-effect profiles?

Core Principles of Psychopharmacology

Before differentiating specific drug classes, it is important to establish the foundational principles that govern how psychotropic medications interact with the nervous system. All psychotropic agents exert their effects by modulating neurotransmission—the chemical signaling process by which neurons communicate across synapses. A drug may alter neurotransmission at multiple points: synthesis of the neurotransmitter, vesicular storage, release, receptor binding, reuptake, or enzymatic degradation. The clinical profile of any medication is determined by which neurotransmitter system(s) it targets, whether it acts as an agonist (facilitating transmission) or antagonist (blocking transmission), and the selectivity with which it binds to receptor subtypes.

Synaptic Mechanisms of Psychotropic Medications

As the diagram illustrates, psychotropic medications can be understood by where they intervene in the synaptic process. Drugs that block reuptake transporters (SSRIs, SNRIs, TCAs) increase the concentration of neurotransmitter in the cleft, thereby prolonging receptor stimulation. Drugs that inhibit degradation enzymes (MAOIs) achieve a similar endpoint through a different mechanism—they prevent the intracellular breakdown of monoamines, leading to greater vesicular stores and release. Meanwhile, receptor antagonists such as typical antipsychotics directly block postsynaptic receptors (primarily D₂), and positive allosteric modulators such as benzodiazepines enhance the receptor's response to endogenous neurotransmitter (GABA). This framework—site of action plus direction of effect—provides the foundation for classifying every psychotropic medication you will encounter on the EPPP.

Mechanisms of Action by Drug Class

Antidepressants

Antidepressants represent the most diverse psychotropic category in terms of mechanism. Selective serotonin reuptake inhibitors (SSRIs)—including fluoxetine, sertraline, paroxetine, citalopram, and escitalopram—selectively block the serotonin transporter (SERT), increasing serotonin availability in the synaptic cleft. Their selectivity for SERT over the norepinephrine transporter (NET) and dopamine transporter (DAT) accounts for their relatively clean side-effect profile compared to older agents. SSRIs are first-line treatments for major depressive disorder (MDD), generalized anxiety disorder (GAD), obsessive-compulsive disorder (OCD), panic disorder, and post-traumatic stress disorder (PTSD).

Serotonin-norepinephrine reuptake inhibitors (SNRIs)—including venlafaxine, duloxetine, and desvenlafaxine—block both SERT and NET. This dual mechanism may confer advantages for patients with comorbid pain conditions or for those who do not respond to SSRIs alone. Indications overlap with SSRIs but extend to chronic pain syndromes and fibromyalgia (particularly duloxetine). Tricyclic antidepressants (TCAs)—such as amitriptyline, nortriptyline, and imipramine—also inhibit SERT and NET but additionally block histamine H₁, muscarinic acetylcholine, and α₁-adrenergic receptors, which explains their significant side effects: sedation, dry mouth, constipation, orthostatic hypotension, and cardiac conduction delays. TCAs are rarely first-line today but remain useful for treatment-resistant depression and certain pain conditions.

Monoamine oxidase inhibitors (MAOIs)—including phenelzine, tranylcypromine, and selegiline—inhibit the enzyme monoamine oxidase, which catabolizes serotonin, norepinephrine, and dopamine. MAO-A preferentially degrades serotonin and norepinephrine, while MAO-B preferentially degrades dopamine. Irreversible MAOIs (phenelzine, tranylcypromine) require strict dietary avoidance of tyramine-containing foods due to the risk of hypertensive crisis. MAOIs are typically reserved for atypical or treatment-resistant depression.

Antipsychotics

Typical (first-generation) antipsychotics (FGAs)—such as haloperidol, chlorpromazine, and fluphenazine—primarily block postsynaptic dopamine D₂ receptors in the mesolimbic pathway, which reduces positive symptoms of schizophrenia (hallucinations, delusions). However, D₂ blockade in the nigrostriatal pathway produces extrapyramidal symptoms (EPS)—akathisia, dystonia, parkinsonism—and chronic use may lead to tardive dyskinesia. Blockade in the tuberoinfundibular pathway elevates prolactin, causing galactorrhea and sexual dysfunction.

Atypical (second-generation) antipsychotics (SGAs)—including clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole—antagonize both D₂ and serotonin 5-HT₂A receptors. The 5-HT₂A antagonism is believed to mitigate EPS by modulating dopamine release in the nigrostriatal pathway. SGAs also address negative symptoms (avolition, flat affect) more effectively than FGAs. Clozapine is uniquely effective for treatment-resistant schizophrenia but requires monitoring for agranulocytosis. Major side effects of SGAs include metabolic syndrome (weight gain, dyslipidemia, hyperglycemia), particularly with olanzapine and clozapine.

Anxiolytics and Mood Stabilizers

Benzodiazepines—including diazepam, lorazepam, alprazolam, and clonazepam—are positive allosteric modulators at the GABA-A receptor. They bind the benzodiazepine site on the receptor complex and increase the frequency of chloride channel opening in response to GABA, thereby enhancing inhibitory neurotransmission. Indications include acute anxiety, panic disorder, seizure management, and procedural sedation. The chief limitations are tolerance, physiological dependence, and cognitive impairment, making them unsuitable for long-term anxiolysis in most cases. Buspirone, by contrast, is a 5-HT₁A partial agonist that treats GAD without sedation, dependence risk, or muscle relaxant properties; its onset is delayed (2–4 weeks).

Mood stabilizers comprise lithium and several anticonvulsants. Lithium's mechanism is not fully elucidated but involves modulation of second-messenger systems, including inhibition of inositol monophosphatase and glycogen synthase kinase-3 (GSK-3). It remains the first-line treatment for bipolar I disorder, with demonstrated efficacy for both acute mania and prophylaxis, as well as an anti-suicidal effect. Valproate enhances GABA transmission and blocks voltage-gated sodium channels, treating acute mania and serving as prophylaxis. Carbamazepine and lamotrigine also modulate sodium channels; lamotrigine is particularly effective for bipolar depression prophylaxis.

Comprehensive Classification Table

The following table synthesizes the major psychotropic medication classes, their primary mechanisms of action, key representatives, primary indications, and notable adverse effects. This classification structure is heavily tested on the EPPP, and you should be able to rapidly associate a drug class with its mechanism, target neurotransmitter system, and clinical use.

Worked Example: Selecting a Medication Based on Mechanism

On the EPPP, you will encounter clinical vignettes that require you to identify the most appropriate medication class based on a patient's diagnosis, symptom profile, and relevant contraindications. The following worked example demonstrates the reasoning process.

Comparing Antidepressant Classes: Strengths and Limitations

One of the most frequently tested areas on the EPPP is the ability to compare antidepressant classes along dimensions of efficacy, safety, side-effect burden, and special considerations. The following table contrasts the four major antidepressant classes across these dimensions, helping you identify which class is appropriate—and which is contraindicated—for a given clinical scenario.

Emerging Mechanisms and Future Directions

While the traditional monoamine-based framework remains the backbone of psychopharmacology tested on the EPPP, newer research has expanded the mechanistic landscape considerably. Understanding these advances provides context for why certain novel agents work differently from established classes and prepares you for questions that reference cutting-edge developments.

For current EPPP preparation, focus on the established drug classes and mechanisms detailed in prior sections. However, be aware that esketamine (Spravato) is FDA-approved for treatment-resistant depression and represents the first mechanistically novel antidepressant in decades—an NMDA receptor antagonist that acts on the glutamate system rather than monoamines. Its rapid onset (hours to days rather than weeks) challenges the longstanding assumption that antidepressant lag time is an intrinsic feature of serotonergic intervention. This evolution from monoamine-centric to multi-system models of psychiatric pharmacology mirrors the broader scientific shift toward understanding mental illness as a disorder of neural circuits and connectivity rather than simple chemical imbalances.

Practice Problems

Key Concepts in Psychotropic Medication Mechanisms